Literature DB >> 7928617

Peritonitis associated with Actinobacillus equuli in horses: 15 cases (1982-1992).

L C Golland1, D R Hodgson, J L Hodgson, M A Brownlow, D R Hutchins, R J Rawlinson, M B Collins, S A McClintock, A L Raisis.   

Abstract

Peritonitis attributable to Actinobacillus equuli was diagnosed in 15 horses examined at the veterinary center between 1982 and 1992. In 13 horses, historical findings included acute onset of mild to severe signs of abdominal pain, lethargy, and inappetence. Two other horses had a history of weight loss for 3 to 6 weeks prior to examination. Diagnosis was based on the physical signs and laboratory findings, including results of peritoneal fluid analysis (gross characteristics, total protein, total and differential nucleated cell counts, and morphologic findings) and culture of A equuli. Actinobacillus equuli was consistently susceptible in vitro to penicillin, trimethoprim/sulfadiazine, and aminoglycosides. All horses in the study had marked clinical improvement within 24 to 48 hours of commencing antibiotic and supportive treatment. Antibiotic treatment was continued for variable periods, depending on the horse, but ranged from 5 to 21 days. In 11 horses for which follow-up information was available, long-term response to treatment was excellent, with horses returning to original activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928617

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Actinobacillus equuli septicemia: an unusual zoonotic infection.

Authors:  C Ashhurst-Smith; R Norton; W Thoreau; M M Peel
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

2.  Clinical features and treatment response to differentiate idiopathic peritonitis from non-strangulating intestinal infarction of the pelvic flexure associated with Strongylus vulgaris infection in the horse.

Authors:  Ylva Hedberg-Alm; Eva Tydén; Lena-Mari Tamminen; Lisa Lindström; Karin Anlén; Maria Svensson; Miia Riihimäki
Journal:  BMC Vet Res       Date:  2022-04-23       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.